Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma|
- Overall Survival [ Time Frame: 9 months ]
- Estimate Progression-free Survival [ Time Frame: 6 months ]
- Estimate Median Progression-Free Survival [ Time Frame: From randomization until progression or death, whichever occurs first, assessed up to 9 months ]
- Estimate Median Overall Survival [ Time Frame: From randomization to death from any cause, assessed up to 9 months ]
- Estimate Overall Response Rate [ Time Frame: From randomization to achievement of either complete response (CR) or partial response (PR), assessed up to 9 months ]
- Estimate Duration of Response Rate [ Time Frame: From the first occurrence of a documented, objective response until the time of relapse or death from any cause, assessed up to 9 months ]
- Number of participants with treatment-related adverse events assessed using NCI CTCAE v.4 [ Time Frame: assessed up to 9 months ]
- Quality of Life [ Time Frame: assessed up to 9 months ]MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)
- Plasma PK [ Time Frame: after first dose ]
|Study Start Date:||January 2017|
|Estimated Primary Completion Date:||March 2020 (Final data collection date for primary outcome measure)|
The dosing regimen for patients will be VAL-083 (40 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation. In patients who demonstrate response or stable disease and tolerate therapy, permission to continue treatment beyond 12 cycles will be considered, but will require consent of the Sponsor.
Recurrent glioblastoma (GBM) is characterized by a dismal prognosis, with a median overall survival of 6-9 months. While a standard of care is established for the initial treatment of GBM - radiation with concurrent and adjuvant temozolomide chemotherapy - management of recurrent disease remains suboptimal. Treatment options include repeat surgery, re-irradiation, or chemotherapy (including experimental targeted therapies, biologic agents, and immunotherapies). Only a minority of patients has response to these treatments, and the resultant benefits in progression-free and overall survival are on the order of weeks to months.
Prognosis and response to therapy are known to be better in patients with a methylated MGMT promoter gene. Epigenetic silencing of MGMT by promoter methylation is an important factor in predicting outcome for patients with GBM treated with temozolomide. Approximately 66% of GBM tumors are MGMT unmethylated (high expression of MGMT), which through a MGMT repair mechanism, confers resistance to temozolomide, the standard chemotherapy treatment of GBM.
VAL-083, Dianhydrogalactitol (DAG), unlike temozolomide, is demonstrated to be active independent of MGMT resistance mechanisms, in vitro. Thus, it may provide a treatment option for those patients that are considered likely to be poor responders to temozolomide.
This is a non-comparative, single arm, biomarker-driven study with VAL-083.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02717962
|Contact: Lorena Lopezfirstname.lastname@example.org|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Active, not recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Barbara O'Brien, M.D.||University of Texas, MDAnderson Cancer Center, Houston, Texas, USA 77030|